NextPlat Corp (NXPL) Form 10-Q — Aug 13, 2026
NextPlat Corp (NXPL) reported Q2 2026 revenue of $11.9 million, down about 10% year over year, but cut its net loss to roughly $144 thousand from $1.8 million a year earlier, with gross margin roughly doubling to about 40% on growth in 340B contract pharmacy revenue and improved drug costing under the Medicare Maximum Fair Price program. The 10-Q discloses that recurring losses and historically negative operating cash flows raised substantial doubt about going concern, but management concluded its mitigation plans — expanding long-term care pharmacy, growing 340B revenue, and adding institutional medication fulfillment contracts — alleviate that doubt.
Key figures
- Revenue
- 11881000
- Total Debt
- 1004000
- Revenue Yoy
- -10.3%
- Cash Position
- 11940000
- Shares Outstanding
- 2713222
- Working capital
- 14200000
- Six month revenue
- 21736000
- Litigation accrual
- 1750000
- Reverse split ratio
- 1:10
- Atm program capacity
- 3800000
- Gross margin q2 2025
- approximately 22%
- Gross margin q2 2026
- approximately 40%
- Six month revenue yoy
- -20%
- Pharmacy acquisition price
- 1500000
Price after filing
Close on the filing date to close N calendar days later (from $6.47). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.